Literature DB >> 22868229

A fluorescent reporter of ATP binding-competent receptor kinases.

Renaud Sicard1, Jyothi Dhuguru, Wenjun Liu, Nirav Patel, Ralf Landgraf, James N Wilson.   

Abstract

ERBB receptor kinases play a crucial role in normal development and cancer malignancies. A broad range of modifications creates receptor subpopulations with distinct functional properties in live cells. Their apparent activation state, typically assayed by tyrosine phosphorylation of substrates, reflects a complex equilibrium of competing reactions. With the aim of developing optical tools to investigate ERBB populations and their state of activation, we have synthesized a fluorescent 'turn-on' probe, DMAQ, targeting the ERBB ATP binding pocket. Upon binding, probe emission increases due to the hydrophobic environment and restricted geometry of the ERBB2 kinase domain, facilitating the analysis of receptor states at low occupancy and without the removal of unbound probes. Cellular ERBB2 autophosphorylation is inhibited with saturation kinetics that correlate with the increase in probe fluorescence. Thus, DMAQ is an example of a new generation of 'turn-on' probes with potential applications in querying receptor kinase populations both in vitro and in live cells.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22868229      PMCID: PMC8087213          DOI: 10.1016/j.bmcl.2012.07.034

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  23 in total

Review 1.  The conformational plasticity of protein kinases.

Authors:  Morgan Huse; John Kuriyan
Journal:  Cell       Date:  2002-05-03       Impact factor: 41.582

2.  Multiplex detection of four pathogenic retroviruses using molecular beacons.

Authors:  J A Vet; A R Majithia; S A Marras; S Tyagi; S Dube; B J Poiesz; F R Kramer
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-25       Impact factor: 11.205

3.  Synthesis and properties of size-expanded DNAs: toward designed, functional genetic systems.

Authors:  Andrew T Krueger; Haige Lu; Alex H F Lee; Eric T Kool
Journal:  Acc Chem Res       Date:  2007-02       Impact factor: 22.384

4.  A quantitative analysis of kinase inhibitor selectivity.

Authors:  Mazen W Karaman; Sanna Herrgard; Daniel K Treiber; Paul Gallant; Corey E Atteridge; Brian T Campbell; Katrina W Chan; Pietro Ciceri; Mindy I Davis; Philip T Edeen; Raffaella Faraoni; Mark Floyd; Jeremy P Hunt; Daniel J Lockhart; Zdravko V Milanov; Michael J Morrison; Gabriel Pallares; Hitesh K Patel; Stephanie Pritchard; Lisa M Wodicka; Patrick P Zarrinkar
Journal:  Nat Biotechnol       Date:  2008-01       Impact factor: 54.908

5.  EGFR activation coupled to inhibition of tyrosine phosphatases causes lateral signal propagation.

Authors:  Andrew R Reynolds; Christian Tischer; Peter J Verveer; Oliver Rocks; Philippe I H Bastiaens
Journal:  Nat Cell Biol       Date:  2003-05       Impact factor: 28.824

6.  A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells.

Authors:  Edgar R Wood; Anne T Truesdale; Octerloney B McDonald; Derek Yuan; Anne Hassell; Scott H Dickerson; Byron Ellis; Christopher Pennisi; Earnest Horne; Karen Lackey; Krystal J Alligood; David W Rusnak; Tona M Gilmer; Lisa Shewchuk
Journal:  Cancer Res       Date:  2004-09-15       Impact factor: 12.701

7.  Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family.

Authors:  G D Plowman; J M Culouscou; G S Whitney; J M Green; G W Carlton; L Foy; M G Neubauer; M Shoyab
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

8.  Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).

Authors:  Stefania Sarno; Erika de Moliner; Maria Ruzzene; Mario A Pagano; Roberto Battistutta; Jenny Bain; Doriano Fabbro; Joseph Schoepfer; Matthew Elliott; Pascal Furet; Flavio Meggio; Giuseppe Zanotti; Lorenzo A Pinna
Journal:  Biochem J       Date:  2003-09-15       Impact factor: 3.857

Review 9.  Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: current status and future directions.

Authors:  Alberto Ocaña; Eitan Amir
Journal:  Cancer Treat Rev       Date:  2009-09-04       Impact factor: 12.111

10.  Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5'-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor.

Authors:  G W Rewcastle; W A Denny; A J Bridges; H Zhou; D R Cody; A McMichael; D W Fry
Journal:  J Med Chem       Date:  1995-09-01       Impact factor: 7.446

View more
  4 in total

1.  Binding-induced, turn-on fluorescence of the EGFR/ERBB kinase inhibitor, lapatinib.

Authors:  James N Wilson; Wenjun Liu; Adrienne S Brown; Ralf Landgraf
Journal:  Org Biomol Chem       Date:  2015-05-07       Impact factor: 3.876

Review 2.  Fluorescent kinase inhibitors as probes in cancer.

Authors:  Syed Muhammad Usama; Bosheng Zhao; Kevin Burgess
Journal:  Chem Soc Rev       Date:  2021-07-22       Impact factor: 60.615

3.  Emission tuning of fluorescent kinase inhibitors: conjugation length and substituent effects.

Authors:  Jyothi Dhuguru; Wenjun Liu; Walter G Gonzalez; W Michael Babinchak; Jaroslava Miksovska; Ralf Landgraf; James N Wilson
Journal:  J Org Chem       Date:  2014-05-08       Impact factor: 4.354

Review 4.  Quinazoline Based HDAC Dual Inhibitors as Potential Anti-Cancer Agents.

Authors:  Jyothi Dhuguru; Ola A Ghoneim
Journal:  Molecules       Date:  2022-03-31       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.